Risk Factors Update Summary
- Completed a follow-on public offering in January 2023 and entered into an At The Market Offering Agreement in February 2024 for up to $5,659,255.
- Accumulated deficit increased from $47,871,900 to $66,900,725 as of December 31, 2023.
- Federal net operating loss carryforwards of approximately $23.1 million and $33.1 million with no expiration as of December 31, 2023.
- State net operating loss carryforwards of approximately $30.2 million as of December 31, 2023, beginning to expire in varying amounts annually from 2030.
- Dr. Werner alone beneficially owned shares representing approximately 19.6% of outstanding common stock as of March 1, 2024.
- Completed a Phase 2 program for the 201 trial with two doses (50 mg and 100 mg) and intends to provide FDA safety and pharmacokinetics data for the 200 mg doses.
- Met with the FDA Review Team in a Pre-NDA meeting on January 19, 2024, to discuss bioequivalence studies of IkT-001Pro.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1750149&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.